Posts Archive

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma The purpose of...

Talquetamab Phase 2 A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma A Study of Talquetamab in...

The clonoSEQ® Watch Registry Real World Observational Study Using clonoSEQ® Next Generation Sequencing in Hematologic Malignancies: The...

NCT04398485: Phase 1: A Study of ION251 Administered to Patients With Relapsed/Refractory Multiple Myeloma A Study of ION251 Administered...

CARTITUDE-4 Ciltacabtagene Autoleucel A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA),...

CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...

AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...

DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...

DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...

Multiple Myeloma Research Consortium MMRC-089: A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3...

ABBV-383 (formerly TNB-383B) TNB-383B, a Bispecific Antibody Targeting BCMA BCMA x CD3 T-cell engaging bispecifc antibody RRMM...

KarMMa-2 An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk...

Multiple Myeloma Research Consortium MyDRUG RRMM NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG) Multiple...

NCT03650491: Phase 1: A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) This study will test the safety...

Multiple Myeloma Research Consortium NCT03030261: Phase 2: Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous...

The GRIFFIN trial Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and...